ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FBLG / forecast
ENVB (34) APRE (40) XCUR (32) BGMS (38) ⌘ Pro Terminal →

FibroBiologics Inc. (FBLG) 12-Month Stock Forecast & Price Target Cone

$0.92 -1.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

FibroBiologics Inc. (FBLG) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $6.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FBLG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.92 (-1.06% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FBLG ranks #582 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FBLG compare to ENVB and APRE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $6.4M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FBLG?
▼

Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $46.6M in revenue (+21.2% YoY), -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.92 (-0.38%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$10 Bull$1 Base$1 Bear
📬 FREE FBLG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FBLG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY FBLG SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 36.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$0.96-4.2% Next Q
Q2 (-2Q)
41
Grade D$0.92+1.1% Next Q
Q3 (-1Q)
39
Grade E$0.93-1.1% Next Q
Current
36
Grade D-$0.92-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FBLG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FBLG currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.29) and Max Pain ($0.97) forces dealer call-delta covering toward $10.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBLG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FBLG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your FBLG Position Size: $10,000

Shares at $0.92: 10869.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.65
$7,065
$-2,935 (-29.3%)
12M Consensus BaseTarget $0.83
$9,022
$-978 (-9.8%)
12M Bull Case BreakoutTarget $10.08
$109,565
+$99,565 (+995.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$969%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBLG)

  • ✓Walkthrough of FBLG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FBLG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.93H $0.93L $0.92C $0.92VOL 20.7K
RES: $2.91SUP: $0.92SMA50: $1.29SMA200: $2.32
$7.76$5.82$3.89$1.95$0.02RES $2.91SUP $0.92$0.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FBLG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FBLG Butterfly Map → + Track FBLG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +21.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FBLG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FBLG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FBLG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBLG)

Health Care Rank #582 of 1015 ⚔️ ENVB vs FBLG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FBLG vs. ENVB, APRE, XCUR, BGMS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, FibroBiologics Inc. (FBLG) ranks #582 by composite RQD confidence (36/100, grade D-) and #924 by equity capitalization ($6.3M). Within this direct 5-issuer industry benchmark cohort, FBLG leads on earnings valuation at N/A trailing P/E, while FBLG leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with FBLG at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FBLG ACTIVE
FibroBiologics Inc.
D- 36/100 — — -35.0% -1.06% $6.3M Benchmark Subject
ENVB
Enveric Biosciences Inc.
E 34/100 — — -35.0% +1.40% $6.4M /envb-vs-fblg →
APRE
Aprea Therapeutics Inc.
D- 40/100 — — -35.0% +1.32% $6.1M /apre-vs-fblg →
XCUR
Exicure Inc.
E 32/100 — — -35.0% +0.99% $6.6M /xcur-vs-fblg →
BGMS
Bio Green Med Solution Inc.
D- 38/100 — — -35.0% 0.00% $6.0M /bgms-vs-fblg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001958777 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), FibroBiologics Inc. (FBLG) reported GAAP revenue of $46.6M (+21.2% vs. FY2024 revenue of $38.5M , and +87.3% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$16.4M, and free cash flow of -$16.7M (-37.8% YoY). On the balance sheet, FBLG closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $46.6M -$18.6M -$16.4M -$16.7M $9.6M —
FY2024 (FY) 2024-12-31 $38.5M -$11.2M -$11.9M -$12.1M $16.4M —
FY2023 (FY) 2023-12-31 $24.9M -$16.5M -$6.4M -$6.4M — —

3. FBLG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.92 (-1.06% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FBLG ranks #582 in composite RQD confidence.

How does FBLG compare to ENVB and APRE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $6.4M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FBLG?

Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $46.6M in revenue (+21.2% YoY), -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FBLG trading relative to its 50-day, 200-day, and 52-week technical levels?

FBLG last traded at $0.92 (-1.06% on volume of 42,420 shares), positioning the stock -28.68% below its 50-day simple moving average ($1.29) and -60.34% below its 200-day simple moving average ($2.32). Across its 52-week range of $0.62 to $9.60, FBLG sits at the 3.3% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.04).

Direct Sub-Reports: FBLG RQD Cockpit FBLG 12M Forecast FBLG Earnings & Move FBLG Dividends & DRIP FBLG Insiders & 13F FBLG Whale Options FBLG Profit Sankey FBLG News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

FBLG — FibroBiologics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

FibroBiologics Inc. (FBLG) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.92 (-1.06% 1D, market capitalization $6.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (FBLG) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. — for specific products, customers, or the mechanism by which the company makes money.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), FibroBiologics Inc. (FBLG) reported $46.6M in annual revenue (up from $38.5M in FY2024, +21.2% YoY) and -$18.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.9M revenue, -$16.5M net income) through FY2025, FBLG scaled operating cash flow to -$16.4M and free cash flow to -$16.7M, backed by $9.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.62 – $9.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream/downstream dependencies or 2nd-order bottlenecks.

  • Key Question #1: Can FBLG sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $46.6M and free cash flow of -$16.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FBLG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FBLG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for FibroBiologics Inc. (FBLG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FBLG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FBLG Bull vs. Bear Conversation Board — What's Your Call at $0.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FBLG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FBLG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.08 (+16.1%)
📌 Pinned Debate

The Roarable RQD rating places Forensic Balance Sheet and Macro Regime Fit at 10/20 each, and the Altman Z-Score of 2.5 and Debt/Equity

Picked up a starter position in FBLG in my $100K Virtual Cash book at $0.93. The Roarable RQD rating places Forensic Balance Sheet and Macro Regime Fit at 10/20 each, and the Altman Z-Score of 2.5 and Debt/Equity of 0.5 are not in distress territory on those measures.. Trading inside a $0.62–$9.60 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $0.93 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.73 (-21.5%)
Spot @ $0.93

Operating income was -$16.6M in FY 2025 against $4.9M of reported cash, with ROIC at -35% and FCF yield at 0%.

Operating income was -$16.6M in FY 2025 against $4.9M of reported cash, with ROIC at -35% and FCF yield at 0%.. Look at the math on FBLG: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.82 before getting long.

LIVE TAPE